APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 185 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $882,946 | -57.2% | 23,211 | +2.4% | 0.01% | -52.9% |
| Q2 2023 | $2,065,237 | +22.2% | 22,670 | -11.6% | 0.02% | +13.3% |
| Q1 2023 | $1,690,621 | +31.8% | 25,631 | +3.3% | 0.02% | +25.0% |
| Q4 2022 | $1,282,460 | -18.9% | 24,801 | +7.1% | 0.01% | -25.0% |
| Q3 2022 | $1,582,000 | +65.1% | 23,158 | +9.3% | 0.02% | +77.8% |
| Q2 2022 | $958,000 | -8.9% | 21,188 | +2.3% | 0.01% | +12.5% |
| Q1 2022 | $1,052,000 | +7.9% | 20,707 | +0.4% | 0.01% | +14.3% |
| Q4 2021 | $975,000 | +79.9% | 20,617 | +25.4% | 0.01% | +75.0% |
| Q3 2021 | $542,000 | -47.7% | 16,445 | +0.4% | 0.00% | -50.0% |
| Q2 2021 | $1,036,000 | +45.9% | 16,386 | -0.9% | 0.01% | +33.3% |
| Q1 2021 | $710,000 | -24.5% | 16,535 | +0.6% | 0.01% | -33.3% |
| Q4 2020 | $941,000 | +71.1% | 16,444 | -9.8% | 0.01% | +80.0% |
| Q3 2020 | $550,000 | +23.9% | 18,227 | +34.0% | 0.01% | -16.7% |
| Q2 2020 | $444,000 | +20.3% | 13,600 | -1.3% | 0.01% | 0.0% |
| Q1 2020 | $369,000 | – | 13,783 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |